Michael M - Search Results

1

Bridging Bio-Nano Science and Cancer Nanomedicine.

Björnmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Björnmalm M, et al. Among authors: michael m. ACS Nano. 2017 Oct 24;11(10):9594-9613. doi: 10.1021/acsnano.7b04855. Epub 2017 Sep 19. ACS Nano. 2017. PMID: 28926225 Review.

2

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR. Michael M, et al. J Clin Oncol. 2006 Sep 10;24(26):4228-35. doi: 10.1200/JCO.2005.04.8496. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896007

3

The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.

Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, Ball D, Michael M, Burman A, Mayura-Guru P, Trapani JA, Peinert S, Hönemann D, Miles Prince H, Scott AM, Smyth MJ, Darcy PK, Kershaw MH. Westwood JA, et al. Among authors: michael m. J Immunother. 2009 Apr;32(3):292-301. doi: 10.1097/CJI.0b013e31819b7c8e. J Immunother. 2009. PMID: 19242371

4

Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.

Khamly K, Jefford M, Michael M, Zalcberg J. Khamly K, et al. Among authors: michael m. Expert Opin Investig Drugs. 2005 Jun;14(6):607-28. doi: 10.1517/13543784.14.6.607. Expert Opin Investig Drugs. 2005. PMID: 16004591 Review.

5

Adjuvant therapy in gastric cancer.

Lim L, Michael M, Mann GB, Leong T. Lim L, et al. Among authors: michael m. J Clin Oncol. 2005 Sep 1;23(25):6220-32. doi: 10.1200/JCO.2005.11.593. J Clin Oncol. 2005. PMID: 16135489 Review.

6

Locally advanced and metastatic gastric cancer: current management and new treatment developments.

Field K, Michael M, Leong T. Field K, et al. Among authors: michael m. Drugs. 2008;68(3):299-317. doi: 10.2165/00003495-200868030-00004. Drugs. 2008. PMID: 18257608 Review.

7

Targeted therapies for gastric cancer: current status.

Yoong J, Michael M, Leong T. Yoong J, et al. Among authors: michael m. Drugs. 2011 Jul 30;71(11):1367-84. doi: 10.2165/11592530-000000000-00000. Drugs. 2011. PMID: 21812503 Review.

8

Potential issues with complementary medicines commonly used in the cancer population: A retrospective review of a tertiary cancer center's experience.

Brooks SL, Rowan G, Michael M. Brooks SL, et al. Among authors: michael m. Asia Pac J Clin Oncol. 2018 Oct;14(5):e535-e542. doi: 10.1111/ajco.13026. Epub 2018 Jun 22. Asia Pac J Clin Oncol. 2018. PMID: 29932300

9

Total neoadjuvant therapy (TNT) in rectal cancer: to or not to give?

Mui M, Kong JCH, Ramsay R, Michael M, Heriot AG. Mui M, et al. Among authors: michael m. ANZ J Surg. 2022 Sep;92(9):1978-1979. doi: 10.1111/ans.17947. ANZ J Surg. 2022. PMID: 36097428 No abstract available.

10

An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.

Lee YC, Michael M, Zalcberg JR. Lee YC, et al. Among authors: michael m. Expert Opin Investig Drugs. 2015;24(10):1307-20. doi: 10.1517/13543784.2015.1070483. Epub 2015 Jul 27. Expert Opin Investig Drugs. 2015. PMID: 26212373 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

983 results

Search Page